Epoch Investment Partners Inc. Decreases Position in Pfizer Inc. (NYSE:PFE)

Epoch Investment Partners Inc. cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 9.3% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 2,068,609 shares of the biopharmaceutical company’s stock after selling 211,933 shares during the period. Epoch Investment Partners Inc.’s holdings in Pfizer were worth $54,880,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PFE. Norges Bank purchased a new position in shares of Pfizer in the fourth quarter valued at $2,328,986,000. Charles Schwab Investment Management Inc. grew its stake in shares of Pfizer by 19.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock valued at $4,124,330,000 after acquiring an additional 25,315,159 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Pfizer during the fourth quarter worth about $274,694,000. Massachusetts Financial Services Co. MA lifted its stake in shares of Pfizer by 7.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock worth $2,029,604,000 after acquiring an additional 5,350,381 shares in the last quarter. Finally, APG Asset Management N.V. boosted its holdings in Pfizer by 1,106.0% in the fourth quarter. APG Asset Management N.V. now owns 5,619,213 shares of the biopharmaceutical company’s stock valued at $143,967,000 after purchasing an additional 5,153,257 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of several analyst reports. Citigroup restated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. UBS Group decreased their price objective on shares of Pfizer from $28.00 to $24.00 and set a “neutral” rating for the company in a report on Tuesday, April 8th. The Goldman Sachs Group restated a “neutral” rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $31.07.

Pfizer Stock Up 0.4 %

Pfizer stock opened at $22.13 on Friday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The stock has a market cap of $125.50 billion, a price-to-earnings ratio of 15.69, a PEG ratio of 0.64 and a beta of 0.67. The company’s 50-day moving average price is $24.88 and its two-hundred day moving average price is $26.17. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same quarter last year, the business earned $0.10 earnings per share. On average, analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.